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Abstract
The multidrug therapy for acquired immunodeﬁciency syndrome (AIDS) is eﬃcacious in suppressing viral load, but it is an inap-
propriate treatment for AIDS patients suﬀering from side eﬀects of anti-human immunodeﬁciency virus (HIV) drugs or who have
developed resistance against these drugs. To cure these patients, alternative AIDS therapy is necessary. In a previous study1, we
discussed the availability of an alternative AIDS treatment that plunges viral activities into chaos by inducing excessive mutations
by mutagenic activity in the HIV RNA genome and established a theoretical basis for its successful use in treatment. However
concurrently mathematical analyses revealed treatment is only successful when the virulence of a virus was relatively low. In this
study, we develop a new treatment to tackle HIV that has high virus virulence by examining the combined eﬀects of a mutagenic
agent and existing anti-HIV drugs. The drugs used include a reverse transcriptase inhibitor and a protease inhibitor. We prove that
a therapy combining drug treatments with a mutagen is superior for its capacity to handle HIV with high virulence and its shorter
treatment duration.
c© 2014 The Authors. Published by Elsevier B.V.
Peer-review under responsibility of KES International.
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1. Introduction
AIDS is a disorder of the immune system caused by HIV infection. Current AIDS treatments mainly depend on
the multidrug therapy known as combination antiretoviral therapy (cART), which consists of at least three diﬀerent
anti-HIV drugs. cART is eﬀective in controlling disease development and suppressing drug resistance; however it
requires lifelong therapy and is no longer eﬀective in certain AIDS patients, such as those who are already resistant
to multiple anti-HIV drugs or who have experienced side eﬀects from them. Considering the many diﬃcult-to-treat
cART patients, an alternative AIDS treatment for cART is necessary. This study focuses on an alternative AIDS
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treatment to kill HIV quasispecies that uses a mutagen to induce excessive mutations beyond the viral genomes’
compensatory capacity. A mutagen is a chemical substrate such as deoxyribonucleoside or ribonucleoside analog that
is mistakenly incorporated into the viral genome by the HIV reverse transcriptase without leading to chain termination
and resulting in mutations. This alternative treatment takes advantage of the error-prone features of the HIV2,3.
Loeb’s et al. indicated the feasibility of an alternative AIDS treatment in vitro4. They used the deoxycytidine
analog C* as a mutagen and demonstrated an absense of viral replication after sequential passages of HIV in human
CEM cells. To apply this technique in vivo, the deoxycitidine analog KP1212 and its prodrug KP1461 were developed.
After successfully completing the phase I clinical study5, a phase II clinical trial for KP1212 and KP1461 extensively
analyzed and validated the drug mechanisms6. This trial involved twice-daily administration of 1600 mg of KP1461
for 124 days. Unexpectedly, the trial showed negative results; the plasma viral loads were not reduced and the overall
levels of viral mutation did not increase, although the mutation spectrum of the HIV genomes were altered. The
reason that the phase II in vivo trial experiments were unsuccessful, in contrast to those in vitro, is unknown. To
gain a mathematical understanding of why the in vivo treatment did not work, we attempted to establish a theoretical
basis for the treatment1 and determined that there was a limitation in the eﬃcacy of the alternative treatment when
using a mutagen. Namely, the treatment is only successful for a virus with relatively low virulence. To overcome
this limitation, this study examines the eﬀects of combining a mutagenic agent and existing anti-HIV drugs, such
as a reverse transcriptase inhibitor and a protease inhibitor. Mathematical analyses prove that the drug treatments
combined with a mutagen are superior to those using only a mutagen with respect to their capacity for handling virus
virulence and their treatment duration.
2. A basic HIV infection and replication model under mutagenic activities
This section proposes a mathematical HIV model that includes HIV infection, replication processes, and mutagenic
action. The proposed model is based on the models developed by Perelson et al. 7 and Wei et al8.
2.1. Phenotypes
The proposed model considers an infectious ability and viral production rate as HIV traits. An infectious HIV with
a high (low) production rate is denoted as V(v), while a noninfectious (fatal) HIV with a high (low) production rate
is denoted as D(d). So there are four HIV phenotypes: V , v, D, and d, where V represents the HIV wildtype. These
phenotypes, with the exception of the wildtype V , appear due to the functional losses of the HIV proteins caused by
mutations. V (v) loses infectivity and changes into D (d) due to the functional loss of HIV protease, which is caused
by mutations at the protease’s active site: Asp25-Thr26-Gly279. The HIV protease creates proteins that are essential
for the progeny virions to remain infectious. V lowers its reproduction rate and changes into v due to the functional
loss of the HIV trans-activator of transcription (Tat) caused by mutations within the genome. HIV Tat is responsible
for the transcriptional activation of HIV gene expression10.
2.2. HIV infection, mutation, and replication processes
Figure 1 illustrates the HIV virion life cycle - the HIV virion infects the host cell, the viral genes mutate, and the
progeny virions bud from the host cell. Free HIV virions die at a rate of c. Uninfected CD4+ T-cells (T ), which are the
host cells for HIV infection, are recruited from the bone marrow at a rate of λ, to the death rate is d. The free virions
V and v infect uninfected CD4+ T-cells at a rate of k. The infected virus then eﬀuses two positive-stranded RNA
genomes into the cytoplasm, and the viral reverse transcriptase uses the positive-strand viral RNA as a template to
transcribe negative-strand viral deoxyribonucleic acid (DNA); then, then the enzyme synthesizes double-strand viral
DNA. However, the transcription is error-prone due to the low ﬁdelity of the reverse transcriptase. Thus, we suggest
that type V viral RNA be transcribed into a type v (D) viral DNA at a mutation rate of pv (pD), while type v viral
RNA be transcribed into type V (d) viral DNA at a mutation rate of qV (qd). The transcribed viral DNA is inserted
into the host cells’ DNA through a cutting and joining mechanism of the HIV integrase. The inserted viral DNA is
called a provirus. However, the viral DNA does not become a provirus from the malfunction of HIV integrase caused
by mutagenesis at its active sites: Asp64, Asp116, Glu15211,12. On the other hand, in terms of type D and d free
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Fig. 1. HIV infection, mutation, and replication processes
virions. The model does not have to consider these types of infection, replication, and mutation processes of type D
and d free virions because they are not infectious. In terms of the viral production process, an infected cell bearing the
provirus V (D) is assumed to produce a total number of virus particles R during its lifetime 1/δ, while those bearing v
(d) produce fewer r virions less than R.
Using the above settings, we developed a mathematical model describing the HIV reproduction process is devel-
oped based on the Perelson model7. The time evolution of PT , which represents uninfected CD4+T-cell populations,
is described in the following time diﬀerential equation (1):
dPT
dt
= λ − dPT − k(Pv + PV )PT , (1)
where viral infection is modeled after a commonly used “mass action” model, for instance kPVPT . On the other hand,
the population of “proviral” CD4+T-cells, bearing the proviruses: V , v, D and d is presented as PTV , PTv , PTD , and
PTd , respectively, and the time evolution of those variables is formulated in the time diﬀerential equations (2-7):
dPTV
dt
= QVkPVPT + qVkPvPT − δPTV , (2)
dPTv
dt
= pvkPVPT + QvkPvPT − δPTv , (3)
dPTD
dt
= pDkPVPT − δPTD , (4)
dPTd
dt
= qdkPvPT − δPTd , (5)
where,
QV ≡ 1 − (pv + pD), (6)
Qv ≡ 1 − (qV + qd). (7)
Equations (6) and (7) note that Qv and QV represent the replication ﬁdelity of HIV v and V , respectively. In the same
way, the viral load of each free virus - V , v, D, and d - is presented as PV , Pv, PD, and Pd, respectively, and the time
evolution of those variables is described in the following time diﬀerential equations (8-11):
dPV
dt
= RδPTV − kPVPT − cPV , (8)
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dPv
dt
= rδPTv − kPvPT − cPv, (9)
dPD
dt
= RδPTD − cPD, (10)
dPd
dt
= rδPTd − cPd. (11)
Finally, we introduce the parameter M (0 < M < 1), which represents the eﬃcacy of a mutagen (M). This
parameter assumes that the enhancement of the mutagen’s eﬃcacy increases with the mutation rate in a linear manner;
thus, each mutation rate, pv, pD, qV , and qd, is modiﬁed as a function of M as in Eqs. (12-15):
pv(M) = p0v + MΔpv, (12)
pD(M) = p0D + MΔpD, (13)
qV (M) = q0V + MΔqV , (14)
qd(M) = q0d + MΔqd, (15)
where parameters p0v, p
0
D, q
0
V and q
0
d represent the original mutation rate.
The parameter values are as follows: λ = 2×104 cells·day−1 ·ml−1, d = 0.01 day−1, δ = 0.7 day−1, k = 10−7 copies−1 ·
ml−1 · day−1, R = 100, r = 10, c = 13 day−1, p0v = 0.05 day−1, p0D = 0.01 day−1, q0V = 0.01 day−1, q0d = 0.01 day−1,
Δpv = 0.15 day−1, ΔpD = 0.3 day−1, ΔqV = 0.01 day−1, and Δqd = 0.3 day−1. The mutation rates and other values
were decieded upon by the references3,13, respectively.
3. A mathematical condition for AIDS treatment eﬀectiveness using a mutagenic approach
3.1. Fully-healed event
The variable sate P is deﬁned as follows:
P = (PT , PTV , PTv , PTD , PTd , PV , Pv, PD, Pd), (16)
and the fully-healed state P∗ is deﬁned as follows:
P∗ = (
λ
d
, 0, 0, 0, 0, 0, 0, 0, 0). (17)
The fully-healed state P∗ is a ﬁxed point in the time diﬀerential equations, (1-11). An initial state P0 for the next
simulations, as deﬁned in Eq. (18), is composed of just one cell infected by the wildtype V and lots of uninfected
cells,
P0 = (
λ
d
, 1, 0, 0, 0, 0, 0, 0, 0). (18)
Using the asymptotic stability analysis at P0 14, the conditions for viral death (P0 is stable) are obtained:
h(M) < gM , (19)
where h(M) and gM are deﬁned in Eqs. (20 and 21), respectively:
h(M) ≡ 12 {h+(M) +
√
h−(M)2 + 4rRqV (M)pv(M)}, (20)
gM ≡ 1 + cdkλ . (21)
h+(M) and h−(M) in Eq. (20) are given in Eqs. (22 and 23), respectively:
h+(M) ≡ rQv(M) + RQV (M), (22)
h−(M) ≡ rQv(M) − RQV (M). (23)
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Fig. 2. A Limitation of the alternative AIDS treatment that uses a mutagen: the functions h(M) and gM were plotted, and the viral production rate
of R is 70.2, 100, and 134. RML and R
M
H are estimated as 70.2 and 134, respectively. This treatment becomes successful only when R is less than
RMH .
3.2. A mathematical limitation of AIDS treatment from a mutagenesis approach
Figure 2 plots the functions h(M) and gM when the viral production rate R is varied. The function h(M) monoton-
ically decreases against M , thus RML and R
M
H are deﬁned as when R satisﬁes h(0) = gM and h(1) = gM , respectively.
RML and R
M
H are given by Eqs. (24 and 25):
RML =
gM(gM − rQv(0))
r(qV (0)pv(0) − Qv(0)QV (0)) + gMQV (0) , (24)
RMH =
gM(gM − rQv(1))
r(qV (1)pv(1) − Qv(1)QV (1)) + gMQV (1) . (25)
A relationship between R and a fully-healed event is summarized as follows:
• When R is less than RML , a fully-healed event occurs independent of M .• When R is geater than RML and less than RMH , a fully-healed event is dependent on M .• When R is greater than RMH , a fully-healed event does not occur independent of M .
In other words, when the viral production rate R is less than RML , the HIV quasispecies population spontaneously dies
without introducing a mutagen. However, when the rate is above RMH , even if the mutagen’s eﬃcacy is perfect, the
mutagen cannot induce the viral death. RMH indicates the limitations of the alternative AIDS treatment based on the
use of a mutagen.
4. A mathematical estimation of the eﬃcacy of drug therapy combined with a mutagen
This section examines various combination eﬀects of a mutagenic agent and existing anti-HIV drugs, such as a
reverse transcriptase inhibitor (RT I) or a protease inhibitor (PI), or both. A synergistic eﬀect is observed in the latter
combination.
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Fig. 3. Limitation of an AIDS treatment by combined use of anti-HIV drugs and a mutagen: the functions h(M ,R) when the viral reproduction
rate R is RMH ,R
M+RT I/M+PI
H , and R
M+RT I+PI
H are plotted. In addition gM , gM+RT I/M+PI , and gM+RT I+PI are described. The relation of gM+RT I/M+PI is
larger than gM , and gM+RT I+PI is larger than gM+RT I/M+PI , are conﬁrmed. Eﬃcacy of the treatment based on the single use of a mutagen is limited
to the case when R is less than RMH (= 134); but by the combined use of the two drugs (RTI and PI) and a mutagen, the upper limit is elevated to
RM+RT I+PIH (=539).
4.1. HIV reverse transcriptase inhibitor
A reverse transcriptase inhibitor targets HIV reverse transcriptase and inhibits the ability of the reverse transciptase-
associated polymerase to synthesize double-strand viral DNA from single-strand viral RNA. Reverse transcriptase
inhibitors suppress the production of proviral host cells. RT I represents the eﬃcacy of a reverse transcriptase inhibitor,
and 0 ≤ RT I ≤ 1. Taking into account the drug eﬃcacy RT I in the time evolution of the diﬀerential equations from
Eq. (1) to Eq. (5), Eq. (1) on the uninfected CD4+ T-cell is modiﬁed to Eq. (26):
dPT
dt
= λ − dPT − k(Pv + PV )PT + RT IkPVPT + RT IkPvPT , (26)
where the fourth and ﬁfth terms are the population of host cells recovered from the V and v infectious state to the
noninfectious state by the reverse transcriptase inhibitors activity. The rest of the equations concerning the proviral
host. Eqs. (2-5), are modiﬁed as in Eqs. (27-30):
dPTV
dt
= (1 − RT I)QV (M)kPVPT + (1 − RT I)qV (M)kPvPT − δPTV , (27)
dPTv
dt
= (1 − RT I)pv(M)kPVPT + (1 − RT I)Qv(M)kPvPT − δPTv , (28)
dPTD
dt
= (1 − RT I)pD(M)kPVPT − δPTD , (29)
dPTd
dt
= (1 − RT I)qd(M)kPvPT − δPTd , (30)
while the change between two phenotypes due to a reverse transcription error occurs when the HIV reverse tran-
scriptase inhibitor does not work suﬃciently. Thus, the term (1 − RT I) is multiplied by all the mathematical terms
representing a mutational change between the two phenotypes.
The asymptotic stability analysis14 clariﬁes the conditions necessary for the fully-healed state P∗ to be stable as in
Eqs. (31 and 32)
h(M) < gM+RT I , (31)
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where
gM+RT I ≡ gM1 − RT I ≈
cd
((1 − RT I)k)λ . (32)
When the reverse transcriptase inhibitor is eﬀective for viral decline (RT I > 0), gM+RT I is larger than gM , the upper
limit RM+RT IH , which is given as R satisfying the requirement that h(1) = gM+RT I , is larger than RH . This is conﬁrmed
in Fig. 3. Thus, the combination of a mutagen and a reverse transcriptase inhibitor can eradicate high virus production;
however, a mutagen alone does not lead to this eradication. According to Eq. (32), the drug eﬃcacy level RT I reduces
the infection rate k by 1 − RT I ; thus, interestingly, 1 − RT I is regarded as the eﬃcacy level of an entry inhibitor. A
currently approved entry inhibitor in Japan is the CCR5 inhibitor, which can block R5-tropic viruses by binding to
CCR5 on host cells, thus, preventing viral invasion into the host cell.
4.2. HIV protease inhibitor
HIV protease cleaves HIV polyproteins in a speciﬁc sequence, Tyr/Phe-Pro, which exists in Gag p17-24, pol p6-
protease, and protease-reverse transcriptase, and creates functional viral proteins. Therefore, this cleaving process
is essential for producing infectious progeny virions. HIV protease inhibitors disrupt the cleaving action of a HIV
protease by binding to the enzymes’ active site, whereupon the progeny virions lose infectivity. When the action of a
protease inhibitor is taken into consideration in the mathematical model, it is found to reduce the viral production rates,
R and r, of the infectious viruses V and v, respectively. Here the eﬃcacy of a HIV protease inhibitor is represented by
PI (0 ≤ PI ≤ 1); Eqs. (8-11) that describe viral growth are modiﬁed as in Eqs. (33-36):
dPV
dt
= (1 − PI)RδPTV − kPVPT − cPV , (33)
dPv
dt
= (1 − PI)rδPTv − kPvPT − cPv, (34)
dPD
dt
= RδPTD + PIRδPTV − cPD, (35)
dPd
dt
= rδPTd + PIrδPTv − cPd. (36)
where the second terms in Eqs. (35 and 36) represent progeny virions deprived of infectivity by the protease inhibitor.
The asymptotic stability analysis14 determines conditions for the fully-healed state P∗ being stable as Eqs. (37 and
38):
h(M) < gM+PI , (37)
where
gM+PI ≡ gM1 − PI . (38)
When the protease inhibitor is eﬀective for viral depression (PI > 0), gM+PI is larger than gM . The upper limit RM+PIH ,
which is given as R satisfying h(1) = gM+PI , is larger than RH . This is conﬁrmed in Fig. 3. Thus, the combined use
of the mutagen together with not only the reverse transcriptase but also the protease inhibitor can eradicate high virus
production, while mutagen alone does not lead to this eradication.
4.3. Both inhibitors
To examine the combined eﬀects of a reverse transcriptase inhibitor and a protease inhibitor together with a mu-
tagen, we considers the mathematical model given by Eqs. (26 - 30) and (33 - 36). Proceeding with the asymptotic
stability analysis14 for the fully-healed state P∗ of the model, the a condition for P∗ being stable is obtained in Eqs.
(39 and 40):
h(M) < gM+RT I+PI , (39)
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where
gM+RI+PI ≡ gM(1 − RT I)(1 − PI) (40)
Equation (40) suggests that the combined use of a reverse transcriptase inhibitor, a protease inhibitor and a mutagen
creates a synergetic eﬀect. The upper limit RM+RT I+PIH , which is given as R satisfying h(1) = gM+RT I+PI , is greater
than RM+RT I/M+PIH . This is conﬁrmed in Fig. 3.
4.4. Treatment duration
Figure 4 shows the decay dynamics of the viral loads (PV ) for the 4 types of treatment methods (single mutagen,
mutagen + RTI(or PI), and mutagen + RTI + PI) are applied to the HIV infectious state. Each of these treatments starts
10 days after the viral infection is established. The treatment using only a mutagen takes about 30 days to establish a
fully-healed state, but the combination therapy using two drugs and a mutagen requires only about 10 days. Thus, the
latter treatment method is superior to the former in terms of not only its capacity to handle HIV with high virulence
but also in its treatment duration.
Fig. 4. Treatment duration: the decay dynamics of viral loads (PV ) when the 4 types of treatment methods (only mutagen, mutagen+RTI(or PI),
and mutagen+RTI+PI) are applied to the HIV infectious state. The values of M , RT I , and PI are 0.5.
5. Conclusions
This study discussed the combined eﬀect of using anti-HIV drugs and a mutagen from a theoretical viewpoint. Our
mathematical analysis demonstrated that treatment with a single anti-HIV drug with a mutagen could eradicate highly
proliferative HIV that is diﬃcult to suppress by mutagenic action alone. Moreover, the combined use of two agents
with a mutagen creates a synergistic eﬀect on viral suppression.
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